Health & MedicineBreaking NewsBreakingLatest News
Anti-Cancer Medicines to Cost Less from November 9 as NPPA Releases Revised MRPs
Sentiment: NeutralHigh Priority
What Happened?
Starting November 9, the NPPA will implement reduced prices for 1,085 anti-cancer medicines, with some brands seeing price cuts of over 80%. The government aims to save patients ₹2,500 crore annually.
Key points
- The NPPA's revised MRP list for 1,085 anti-cancer medicines will take effect on November 9.
- The price revision follows an October 17 announcement enforcing trade margin rationalisation on 137 non-scheduled anti-cancer drugs.
- Retail prices are expected to decrease by up to 70%, leading to estimated annual savings of ₹2,500 crore for patients.
- Significant price cuts include Zydus Lifesciences’ Bryxta dropping from ₹76,924 to ₹11,884.
- Patients can check revised prices on the Pharma Sahi Daam app or NPPA website.
Key insights
- The price cuts may increase access to essential cancer treatments for many patients.
- Hospitals and pharmacies will need to adjust their pricing structures to comply with the new MRPs.
- The government's ongoing efforts to regulate drug prices could lead to further reductions in healthcare costs.
Why it matters
This price reduction could significantly ease the financial burden on cancer patients in India.
Source
Times Now
